Kristin Kramer woke up early on a Tuesday morning 10 years ago because one of her dogs needed to go out. Then, a couple of odd things happened. When she tried to call her other dog, “I couldn’t speak,” she said. As she walked downstairs to let them into the yard, “I noticed that my…
Gilead Sciences exercised its option license a Kymera Therapeutics’ protein-degrading drug designed to eliminate the cancer-driving protein CDK2. Meanwhile, Roche’s new partnership with C4 Therapeutics is focused on developing degrader antibody drug conjugates for undisclosed cancer targets. The post Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines appeared first on MedCity…
The weight loss results for the Terns Pharmaceuticals drug TERN-601 come from a four-week Phase 1 clinical trial. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class. The post Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight…
That is the tile of my recent paper in the Journal of Medical Economics with co-authors Kyi-Sin Than, Sanjana Muthukrishnan, Jincy Paulose, Ver Bilano and Nicholas Kuypers. The abstract is below: ObjectiveParoxysmal nocturnal hemoglobinuria (PNH) is a rare and debilitating hematological disease with significant economic burden. Despite the availability of multiple therapies, there is a…
By TOMMY BEVERIDGE Just like the Holy Roman Empire was none of those things, America’s health care system is neither health care, nor a system. Both are in fact decentralized commercial arrangements clothed in things that sound good, like Holy-Romanness, or Consumer-driven Health Care. Rather than health care, we have a patchwork of consumer products and government…
The KFF Survey of Women Voters examines differing motivations, attitudes, and experiences among women by race and ethnicity, age, and partisanship heading into the 2024 election nationally and in two battleground states, Arizona and Michigan.
KINGSTREE, S.C. — One morning in late April, a small brick health clinic along the Thurgood Marshall Highway bustled with patients. There was Joshua McCray, 69, a public bus driver who, four years after catching covid-19, still is too weak to drive. Louvenia McKinney, 77, arrived complaining about shortness of breath. Ponzella McClary brought her…
Draig Therapeutics’ lead drug is designed to safely target the AMPA receptor as a way of mediating the interplay between two neurotransmitters whose imbalance is associated with mood disorders. The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or entering clinical testing. The post…
Duke University Health System is deploying a mix of homegrown and purchased AI tools to ease clinicians’ administrative burden and improve patient care. Chief Nurse Executive Terry McDonnell highlighted that while AI can’t replace nurses’ judgment, it can help free up their time for what matters most. The post Inside Duke’s Approach to Building and…
Randomized controlled trials are the gold standard for evaluating treatment efficacy, but effectiveness in the real-world may vary. One reason for this is that clinical trials often have stricter inclusion criteria than is the case for the target treated population. Policymakers, payers, and clinicians may wonder how well the results from the narrower clinical trial…